Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Linsitinib | 0.0033113 | uM | 9 | 156.25 | 92.36 | 131.00 | 144.75 | 0.9050 | 0.7146 |
| SK-BR-3 | 17-AAG | 0.01 | uM | 9 | 156.25 | 92.36 | 74.00 | 144.75 | 0.5112 | -0.2897 |
| SK-BR-3 | Lapatinib | 3.1623 | uM | 9 | 156.25 | 92.36 | 107.00 | 144.75 | 0.7392 | 0.2548 |
| SK-BR-3 | 17-AAG | 0.001 | uM | 9 | 156.25 | 92.36 | 170.00 | 144.75 | 1.1744 | 1.5631 |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 127.00 | 144.75 | 0.8774 | 0.6345 | |
| SK-BR-3 | 17-AAG | 0.0031623 | uM | 9 | 156.25 | 92.36 | 126.00 | 144.75 | 0.8705 | 0.6147 |
| SK-BR-3 | Linsitinib | 1 | uM | 9 | 156.25 | 92.36 | 99.00 | 144.75 | 0.6839 | 0.1130 |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 115.00 | 144.75 | 0.7945 | 0.4024 | |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 32.00 | 144.75 | 0.2211 | -0.8051 | |
| SK-BR-3 | Linsitinib | 19.9526 | uM | 9 | 156.25 | 92.36 | 96.00 | 144.75 | 0.6632 | 0.0614 |
| SK-BR-3 | Linsitinib | 3.1623 | uM | 9 | 156.25 | 92.36 | 137.00 | 144.75 | 0.9465 | 0.8372 |
| SK-BR-3 | Lapatinib | 0.0033113 | uM | 9 | 156.25 | 92.36 | 222.00 | 144.75 | 1.5337 | 2.8689 |
| SK-BR-3 | Erlotinib | 0.0033113 | uM | 9 | 156.25 | 92.36 | 178.00 | 144.75 | 1.2297 | 1.7515 |
| SK-BR-3 | Linsitinib | 0.1 | uM | 9 | 156.25 | 92.36 | 141.00 | 144.75 | 0.9741 | 0.9206 |
| SK-BR-3 | Lapatinib | 0.1 | uM | 9 | 156.25 | 92.36 | 95.00 | 144.75 | 0.6563 | 0.0444 |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 188.00 | 144.75 | 1.2988 | 1.9936 | |
| SK-BR-3 | 17-AAG | 0.000066069 | uM | 9 | 156.25 | 92.36 | 163.00 | 144.75 | 1.1261 | 1.4021 |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 232.00 | 144.75 | 1.6028 | 3.1410 | |
| SK-BR-3 | Linsitinib | 0.01 | uM | 9 | 156.25 | 92.36 | 184.00 | 144.75 | 1.2712 | 1.8959 |
| SK-BR-3 | 17-AAG | 0.1 | uM | 9 | 156.25 | 92.36 | 77.00 | 144.75 | 0.5320 | -0.2447 |
| SK-BR-3 | Lapatinib | 0.01 | uM | 9 | 156.25 | 92.36 | 137.00 | 144.75 | 0.9465 | 0.8372 |
| SK-BR-3 | Lapatinib | 0.31623 | uM | 9 | 156.25 | 92.36 | 137.00 | 144.75 | 0.9465 | 0.8372 |
| SK-BR-3 | 17-AAG | 0.31623 | uM | 9 | 156.25 | 92.36 | 61.00 | 144.75 | 0.4214 | -0.4727 |
| SK-BR-3 | Erlotinib | 0.1 | uM | 9 | 156.25 | 92.36 | 293.00 | 144.75 | 2.0242 | 4.9363 |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 177.00 | 144.75 | 1.2228 | 1.7277 |